The phase I/II clinical trials of TO-O-1001 approved by the Australian Human Research Ethics Committee (HREC) on 4 Aug 2022.
Aug 04, 2022 The company leading clinical project, TO-O-1001 eye drops (NCT05456724), as a novel glaucoma treatment is now approved by the Australian Human Research Ethics Committee (HREC) for Phase I/II human trials in healthy volunteers and in patients. The first-in-human dosing shall begin by the end of this month, and the phase II trial with glaucoma patients is expected to kick in by the end of this year.
The global ophthalmic drug market size has reached 36.7 billion US dollars in 2020, and is growing rapidly at a CAGR of 8.5%. It is further estimated the global ophthalmic drug market should reach $70.49 billion in 2028.